Gene Transfer Explored As Way to Up LV Function in Heart Failure

This article originally appeared here.
Share this content:
Gene Transfer Explored As Way to Up LV Function in Heart Failure
Gene Transfer Explored As Way to Up LV Function in Heart Failure

WEDNESDAY, March 30, 2016 (HealthDay News) -- Intracoronary delivery of adenovirus 5 encoding adenylyl cyclase 6 (Ad5.hAC6) is safe for patients with heart failure and reduced ejection fraction (EF), according to a study published online March 30 in JAMA Cardiology.

H. Kirk Hammond, M.D., from the Veterans Affairs San Diego Healthcare System, and colleagues screened participants with symptomatic heart failure and EF of ≤40 percent and randomized 56 patients in a 3:1 ratio to receive one of five doses of intracoronary Ad5.hAC6 or placebo. Fourteen placebo participants were compared with 24 participants receiving the highest two doses of Ad5.hAC6 (D4 + 5).

The researchers observed no significant group differences in exercise duration at four or 12 weeks. At four weeks, but not 12 weeks, the D4 + 5 participants had increased EF. No increase in EF was seen at four or 12 weeks in the placebo group. There were no between-group differences noted in exercise duration. Increased basal left ventricular peak pressure decline was seen with AC6 gene transfer; increased arrhythmias were not seen with AC6 gene transfer. For patients with heart failure, the admission rate was 9.5 and 28.6 percent in the AC6 and placebo groups, respectively (relative risk, 0.33; 95 percent confidence interval, 0.08 to 1.36; P = 0.10).

"Larger trials are warranted to assess the safety and efficacy of AC6 gene transfer for patients with heart failure," the authors write.

Several authors disclosed financial ties to pharmaceutical and biotechnology companies, including Renova Therapeutics, which partially funded the study.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »